Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The platform’s technology works as a compression algorithm for molecular testing
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Sputnik M is a new member of the Sputnik vaccines family
Subscribe To Our Newsletter & Stay Updated
